Camelia Quek

5.3k total citations · 2 hit papers
37 papers, 2.5k citations indexed

About

Camelia Quek is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Camelia Quek has authored 37 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 17 papers in Immunology and 16 papers in Molecular Biology. Recurrent topics in Camelia Quek's work include Cancer Immunotherapy and Biomarkers (17 papers), Immunotherapy and Immune Responses (14 papers) and CAR-T cell therapy research (13 papers). Camelia Quek is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Immunotherapy and Immune Responses (14 papers) and CAR-T cell therapy research (13 papers). Camelia Quek collaborates with scholars based in Australia, United States and Vietnam. Camelia Quek's co-authors include Andrew F. Hill, Georgina V. Long, James S. Wilmott, Richard A. Scolyer, Antony W. Burgess, Lahiru Gangoda, Johnson I. Agbinya, Oliver M. Sieber, Agus Salim and Dmitri Mouradov and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer.

In The Last Decade

Camelia Quek

36 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FunRich: An open access standalone functional enrichment and interaction network analysis tool

2015 980 citations Camelia Quek, Andrew F. Hill et al. profile →
Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

2019 412 citations Imran G. House, Peter Savas et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Camelia Quek

Since Specialization

Citations

This map shows the geographic impact of Camelia Quek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Camelia Quek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Camelia Quek more than expected).

Fields of papers citing papers by Camelia Quek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Camelia Quek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Camelia Quek. The network helps show where Camelia Quek may publish in the future.

Co-authorship network of co-authors of Camelia Quek

This figure shows the co-authorship network connecting the top 25 collaborators of Camelia Quek. A scholar is included among the top collaborators of Camelia Quek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Camelia Quek. Camelia Quek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Naegleria fowleri: Portrait of a Cerebral Killer 2025 ·Diagnostics ·(unknown), (unknown), (unknown), Vi Am Dinh, (unknown), (unknown), (unknown), Thanh Nguyen, (unknown), T. Le-Xuan, Camelia Quek, Van Hung Pham, Son Pham	1
2	Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma 2024 ·Nature Communications ·(unknown), Grace H. Attrill, Tuba N. Gide, Peter M. Ferguson, (unknown), Ping Shang, Ismael A. Vergara, Umaimainthan Palendira, Inês Pires da Silva, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long, Richard A. Scolyer, James S. Wilmott, Camelia Quek	4
3	Single-Cell Informatics for Tumor Microenvironment and Immunotherapy 2024 ·International Journal of Molecular Sciences ·(unknown), (unknown), Camelia Quek	3
4	Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses 2024 ·International Journal of Molecular Sciences ·(unknown), Camelia Quek	11
5	Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach 2023 ·Journal of Translational Medicine ·(unknown), Tuba N. Gide, Nurudeen A. Adegoke, Camelia Quek, (unknown), Alison J. Potter, Ellis Patrick, Robyn P.M. Saw, John F. Thompson, Andrew J. Spillane, Kerwin F. Shannon, Matteo S. Carlino, Serigne Lo, Alexander M. Menzies, Inês Pires da Silva, Georgina V. Long, Richard A. Scolyer, James S. Wilmott	6
6	1165P Single cell spatial features of in-transit melanoma associated with patient outcome to immunotherapy 2023 ·Annals of Oncology ·Xue Bai, Camelia Quek, Ghamdan Al‐Eryani, Kate Harvey, Inês Pires da Silva, Alexander M. Menzies, Alexander Swarbrick, Georgina V. Long, Richard A. Scolyer, James S. Wilmott	1
7	Non-Antigenic Modulation of Antigen Receptor (TCR) Cβ-FG Loop Modulates Signalling: Implications of External Factors Influencing T-Cell Responses 2023 ·International Journal of Molecular Sciences ·Nicholas Manolios, Son Pham, (unknown), Jonathan J. Du, Camelia Quek, David E. Hibbs	1
8	Abstract 4621: Distinct spatial and molecular maps in the tumour microenvironment of resistant melanoma patients treated with checkpoint inhibitor immunotherapy 2023 ·Cancer Research ·Camelia Quek, Aditya Pratapa, Inês Pires da Silva, Ghamdan Al‐Eryani, Aaron T. Mayer, Nenad Bartoniček, Kate Harvey, Oliver Braubach, Robyn P.M. Saw, Jonathan R. Stretch, Kerwin F. Shannon, Alexander M. Menzies, Richard A. Scolyer, Georgina V. Long, Alexander Swarbrick, James S. Wilmott	0
9	Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis 2022 ·JCI Insight ·(unknown), Felix Marsh‐Wakefield, Robert V. Rawson, Tuba N. Gide, Angela L. Ferguson, (unknown), Camelia Quek, Inês Pires da Silva, (unknown), (unknown), Neomal S. Sandanayake, Matteo S. Carlino, Geoffrey W. McCaughan, James S. Wilmott, Richard A. Scolyer, Georgina V. Long, Alexander M. Menzies, Umaimainthan Palendira	10
10	Characteristics of Hepatitis B Virus Genotype and Sub-Genotype in Hepatocellular Cancer Patients in Vietnam 2022 ·Diagnostics ·(unknown), Mario Giosuè Balzanelli, (unknown), (unknown), (unknown), Christine Nguyen, (unknown), (unknown), Son Pham, Huy Nguyen, (unknown), Manh‐Toan Ho, Gianna Dipalma, Francesco Inchingolo, Camelia Quek, Thị Thu Hương Phạm, Ciro Gargiulo Isacco, Luigì Santacroce, (unknown)	5
11	Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma 2022 ·Frontiers in Molecular Biosciences ·(unknown), Tuba N. Gide, (unknown), Alison J. Potter, Camelia Quek, Angela Hong, Georgina V. Long, Richard A. Scolyer, James S. Wilmott	17
12	Distribution of microRNA profiles in pre-clinical and clinical forms of murine and human prion disease 2021 ·Communications Biology ·Lesley Cheng, Camelia Quek, Xia Li, Shayne A. Bellingham, (unknown), Mitch Shambrook, Saima Zafar, Inga Zerr, Victoria Lawson, Andrew F. Hill	10
13	Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials 2019 ·Clinical Cancer Research ·Jarem Edwards, Annie Tasker, Inês Pires da Silva, Camelia Quek, Marcel Batten, Angela L. Ferguson, (unknown), (unknown), Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies, Umaimainthan Palendira, James S. Wilmott, Georgina V. Long, Richard A. Scolyer	26
14	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade breakdown → 2019 ·Clinical Cancer Research ·Imran G. House, Peter Savas, Junyun Lai, Amanda X. Y. Chen, Amanda J. Oliver, Zhi L. Teo, Kirsten L. Todd, Melissa A. Henderson, Lauren Giuffrida, Emma V. Petley, Kevin Sek, Sherly Mardiana, Tuba N. Gide, Camelia Quek, Richard A. Scolyer, Georgina V. Long, James S. Wilmott, Sherene Loi, Phillip K. Darcy, Paul A. Beavis	412
15	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF -Mutant Melanoma 2019 ·Clinical Cancer Research ·Inês Pires da Silva, Kevin Wang, James S. Wilmott, Jeff Holst, Matteo S. Carlino, John Park, Camelia Quek, Matthew Wongchenko, Yibing Yan, Graham J. Mann, Douglas B. Johnson, Jennifer L. McQuade, Rajat Rai, Richard Kefford, Helen Rizos, Richard A. Scolyer, Jean Yang, Georgina V. Long, Alexander M. Menzies	48
16	Novel miR-29b target regulation patterns are revealed in two different cell lines 2019 ·Scientific Reports ·(unknown), Lesley Cheng, Camelia Quek, Shayne A. Bellingham, Andrew F. Hill	12
17	Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy 2019 ·Cancer ·Inês Pires da Silva, Serigne Lo, Camelia Quek, Maria Gonzalez, Matteo S. Carlino, Georgina V. Long, Alexander M. Menzies	108
18	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment 2018 ·Clinical Cancer Research ·Jarem Edwards, James S. Wilmott, Jason Madore, Tuba N. Gide, Camelia Quek, Annie Tasker, Angela L. Ferguson, Jinbiao Chen, Rehana Hewavisenti, Peter Hersey, Thomas Gebhardt, Wolfgang Weninger, Warwick J. Britton, Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies, Georgina V. Long, Richard A. Scolyer, Umaimainthan Palendira	317
19	Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples 2018 ·Journal of Molecular Diagnostics ·F. Lamoury, Behzad Hajarizadeh, (unknown), (unknown), Camelia Quek, Philip Cunningham, Beth Catlett, Gavin Cloherty, Philippa Marks, Janaki Amin, Jason Grebely, Gregory J. Dore, Tanya Applegate	19
20	Gene dysregulation is restored in the Parkinson’s disease MPTP neurotoxic mice model upon treatment of the therapeutic drug CuII(atsm) 2016 ·Scientific Reports ·Lesley Cheng, Camelia Quek, Lin W. Hung, Robyn A. Sharples, (unknown), Kevin J. Barnham, Andrew F. Hill	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact